High threshold of β1 integrin inhibition required to block collagen I-induced membrane type-1 matrix metalloproteinase (MT1-MMP) activation of matrix metalloproteinase 2 (MMP-2)

Cancer Cell International

Erik W Thompson¹  Marc A Lafleur²  Tony Blick¹  Prasit Pavasant³  Kulrut Borrirukwanit² 

[1] Institute of Health and Biomedical Innovation and School of Biomedical Sciences, Queensland University of Technology, Kelvin Grove, Queensland, Australia;Invasion and Metastasis Unit, St. Vincent’s Institute, Fitzroy 3065, Victoria, Australia;Department of Anatomy, Faculty of Dentistry, Chulalongkorn University, Chulalongkorn, Thailand

关键词: Invasion and metastasis;    Type I collagen;    MMP-2 activation;    Matrix metalloproteinase;    β1 Integrin;   

Others  :  1121651
DOI  :  10.1186/s12935-014-0099-3

 received in 2014-04-16, accepted in 2014-09-21,  发布年份 2014

【 摘 要 】

Background

Matrix metalloproteinase-2 (MMP-2) is an endopeptidase that facilitates extracellular matrix remodeling and molecular regulation, and is implicated in tumor metastasis. Type I collagen (Col I) regulates the activation of MMP-2 through both transcriptional and post-transcriptional means; however gaps remain in our understanding of the involvement of collagen-binding β1 integrins in collagen-stimulated MMP-2 activation.

Methods

Three β1 integrin siRNAs were used to elucidate the involvement of β1 integrins in the Col I-induced MMP-2 activation mechanism. β1 integrin knockdown was analyzed by quantitative RT-PCR, Western Blot and FACS analysis. Adhesion assay and collagen gel contraction were used to test the biological effects of β1 integrin abrogation. MMP-2 activation levels were monitored by gelatin zymography.

Results

All three β1 integrin siRNAs were efficient at β1 integrin knockdown and FACS analysis revealed commensurate reductions of integrins α2 and α3, which are heterodimeric partners of β1, but not αV, which is not. All three β1 integrin siRNAs inhibited adhesion and collagen gel contraction, however only the siRNA showing the greatest magnitude of β1 knockdown inhibited Col I-induced MMP-2 activation and reduced the accompanying upregulation of MT1-MMP, suggesting a dose response threshold effect. Re-transfection with codon-swapped β1 integrin overcame the reduction in MMP-2 activation induced by Col-1, confirming the β1 integrin target specificity. MMP-2 activation induced by TPA or Concanavalin A (Con A) was not inhibited by β1 integrin siRNA knockdown.

Conclusion

Together, the data reveals that strong abrogation of β1 integrin is required to block MMP-2 activation induced by Col I, which may have implications for the therapeutic targeting of β1 integrin.

【 授权许可】

   
2014 Borrirukwanit et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

【 参考文献 】

• [1]Humphries MJ: Integrin structure. Biochem Soc Trans 2000, 28:311-339.
• [2]Schatzmann F, Marlow R, Streuli CH: Integrin signaling and mammary cell function. J Mammary Gland Biol Neoplasia 2003, 8:395-408.
• [3]Elliott BE, Ekblom P, Pross H, Niemann A, Rubin K: Anti-beta 1 integrin IgG inhibits pulmonary macrometastasis and the size of micrometastases from a murine mammary carcinoma. Cell Adhes Commun 1994, 1:319-332.
• [4]Fujita S, Watanabe M, Kubota T, Teramoto T, Kitajima M: Alteration of expression in integrin beta 1-subunit correlates with invasion and metastasis in colorectal cancer. Cancer Lett 1995, 91:145-149.
• [5]Cordes N, Park CC: beta1 integrin as a molecular therapeutic target. Int J Radiat Biol 2007, 83:753-760.
• [6]Lynch CC, Matrisian LM: Matrix metalloproteinases in tumor-host cell communication. Differentiation 2002, 70:561-573.
• [7]Overall CM, Kleifeld O: Tumour microenvironment - opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nat Rev Cancer 2006, 6:227-239.
• [8]Fingleton B: Matrix metalloproteinases: roles in cancer and metastasis. Front Biosci 2006, 11:479-491.
• [9]Egeblad M, Werb Z: New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002, 2:161-174.
• [10]Noel AC, Polette M, Lewalle JM, Munaut C, Emonard HP, Birembaut P, Foidart JM: Coordinate enhancement of gelatinase A mRNA and activity levels in human fibroblasts in response to breast-adenocarcinoma cells. Int J Cancer 1994, 56:331-336.
• [11]Dalberg K, Eriksson E, Enberg U, Kjellman M, Backdahl M: Gelatinase A, membrane type 1 matrix metalloproteinase, and extracellular matrix metalloproteinase inducer mRNA expression: correlation with invasive growth of breast cancer. World J Surg 2000, 24:334-340.
• [12]Visse R, Nagase H: Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res 2003, 92:827-839.
• [13]Itoh Y, Seiki M: MT1-MMP: an enzyme with multidimensional regulation. Trends Biochem Sci 2004, 29:285-289.
• [14]Sato H, Takino T, Okada Y, Cao J, Shinagawa A, Yamamoto E, Seiki M: A matrix metalloproteinase expressed on the surface of invasive tumour cells. Nature 1994, 370:61-65.
• [15]Sato H, Takino T, Kinoshita T, Imai K, Okada Y, Stetler Stevenson WG, Seiki M: Cell surface binding and activation of gelatinase A induced by expression of membrane-type-1-matrix metalloproteinase (MT1-MMP). FEBS Lett 1996, 385:238-240.
• [16]Strongin AY, Collier I, Bannikov G, Marmer BL, Grant GA, Goldberg GI: Mechanism of cell surface activation of 72-kda type IV collagenase. Isolation of the activated form of the membrane metalloprotease. J Biol Chem 1995, 270:5331-5338.
• [17]Azzam HS, Thompson EW: Collagen-induced activation of the M(r) 72,000 type IV collagenase in normal and malignant human fibroblastoid cells. Cancer Res 1992, 52:4540-4544.
• [18]Thompson EW, Yu M, Bueno J, Jin L, Maiti SN, Palao-Marco FL, Pulyaeva H, Tamborlane JW, Tirgari R, Wapnir I, Azzam H: Collagen induced MMP-2 activation in human breast cancer. Breast Cancer Res Treat 1994, 31:357-370.
• [19]Haas TL, Davis SJ, Madri JA: Three-dimensional type I collagen lattices induce coordinate expression of matrix metalloproteinases MT1-MMP and MMP-2 in microvascular endothelial cells. J Biol Chem 1998, 273:3604-3610.
• [20]Deryugina EI, Bourdon MA, Reisfeld RA, Strongin A: Remodeling of collagen matrix by human tumor cells requires activation and cell surface association of matrix metalloproteinase-2. Cancer Res 1998, 58:3743-3750.
• [21]Ellerbroek SM, Wu YI, Overall CM, Stack MS: Functional interplay between type I collagen and cell surface matrix metalloproteinase activity. J Biol Chem 2001, 276:24833-24842.
• [22]Kim IY, Jeong SJ, Kim ES, Kim SH, Moon A: Type I collagen-induced pro-MMP-2 activation is differentially regulated by H-Ras and N-Ras in human breast epithelial cells. J Biochem Mol Biol 2007, 40:825-831.
• [23]Gilles C, Polette M, Seiki M, Birembaut P, Thompson EW: Implication of collagen type I-induced membrane-type 1-matrix metalloproteinase expression and matrix metalloproteinase-2 activation in the metastatic progression of breast carcinoma. LabInvest 1997, 76:651-660.
• [24]Lafleur MA, Mercuri FA, Ruangpanit N, Seiki M, Sato H, Thompson EW: Type I collagen abrogates the clathrin-mediated internalization of membrane type 1 matrix metalloproteinase (MT1-MMP) via the MT1-MMP hemopexin domain. J Biol Chem 2006, 281:6826-6840.
• [25]Prockop DJ, Kivirikko KI: Collagens: molecular biology, diseases, and potentials for therapy. Annu Rev Biochem 1995, 64:403-434.
• [26]Shoulders MD, Raines RT: Collagen structure and stability. Annu Rev Biochem 2009, 78:929-958.
• [27]Jokinen J, Dadu E, Nykvist P, Kapyla J, White DJ, Ivaska J, Vehvilainen P, Reunanen H, Larjava H, Hakkinen L, Heino J: Integrin-mediated cell adhesion to type I collagen fibrils. J Biol Chem 2004, 279:31956-31963.
• [28]Ellerbroek SM, Fishman DA, Kearns AS, Bafetti LM, Stack MS: Ovarian carcinoma regulation of matrix metalloproteinase-2 and membrane type 1 matrix metalloproteinase through beta1 integrin. Cancer Res 1999, 59:1635-1641.
• [29]Tang Y, Rowe RG, Botvinick EL, Kurup A, Putnam AJ, Seiki M, Weaver VM, Keller ET, Goldstein S, Dai J, Begun D, Saunders T, Weiss SJ: MT1-MMP-dependent control of skeletal stem cell commitment via a β1-integrin/YAP/TAZ signaling axis. Dev Cell 2013, 25:402-416.
• [30]Mori H, Lo AT, Inman JL, Alcaraz J, Ghajar CM, Mott JD, Nelson CM, Chen CS, Zhang H, Bascom JL, Seiki M, Bissell MJ: Transmembrane/cytoplasmic, rather than catalytic, domains of Mmp14 signal to MAPK activation and mammary branching morphogenesis via binding to integrin β1. Development 2013, 140:343-352.
• [31]Sakai K, Nakamura T, Suzuki Y, Imizu T, Matsumoto K: 3-D collagen-dependent cell surface expression of MT1-MMP and MMP-2 activation regardless of integrin beta1 function and matrix stiffness. Biochem Biophys Res Commun 2011, 412:98-103.
• [32]Pulyaeva H, Bueno J, Polette M, Birembaut P, Sato H, Seiki M, Thompson EW: MT1-MMP correlates with MMP-2 activation potential seen after epithelial to mesenchymal transition in human breast carcinoma cells. Clin Exp Metastasis 1997, 15:111-120.
• [33]Gilles C, Bassuk JA, Pulyaeva H, Sage EH, Foidart JM, Thompson EW: SPARC/osteonectin induces matrix metalloproteinase 2 activation in human breast cancer cell lines. Cancer Res 1998, 58:5529-5536.
• [34]Lafleur MA, Drew AF, de Sousa EL, Blick T, Bills M, Walker EC, Williams ED, Waltham M, Thompson EW: Upregulation of matrix metalloproteinases (MMPs) in breast cancer xenografts: a major induction of stromal MMP-13. Int J Cancer 2005, 114:544-554.
• [35]Tulla M, Pentikainen OT, Viitasalo T, Kapyla J, Impola U, Nykvist P, Nissinen L, Johnson MS, Heino J: Selective binding of collagen subtypes by integrin alpha 1I, alpha 2I, and alpha 10I domains. J Biol Chem 2001, 276:48206-48212.
• [36]Hynes RO: Integrins: bidirectional, allosteric signaling machines. Cell 2002, 110:673-687.
• [37]Green LJ, Mould AP, Humphries MJ: The integrin beta subunit. Int J Biochem Cell Biol 1998, 30:179-184.
• [38]Holmbeck K, Bianco P, Caterina J, Yamada S, Kromer M, Kuznetsov SA, Mankani M, Robey PG, Poole AR, Pidoux I, Ward JM, Birkedal-Hansen H: MT1-MMP-deficient mice develop dwarfism, osteopenia, arthritis, and connective tissue disease due to inadequate collagen turnover. Cell 1999, 99:81-92.
• [39]Ruangpanit N, Chan D, Holmbeck K, Birkedal-Hansen H, Polarek J, Yang C, Bateman JF, Thompson EW: Gelatinase A (MMP-2) activation by skin fibroblasts: dependence on MT1-MMP expression and fibrillar collagen form. Matrix Biol 2001, 20:193-203.
• [40]Kim NV: RNA interference in functional genomics and medicine. J Korean Med Sci 2003, 18:309-318.
• [41]Lipardi C, Wei Q, Paterson BM: RNAi as random degradative PCR. siRNA primers convert mRNA into dsRNA that are degraded to generate new siRNAs. Cell 2001, 107:297-307.
• [42]Guo W, Giancotti FG: Integrin signalling during tumour progression. Nat Rev Mol Cell Biol 2004, 5:816-826.
• [43]Larsen M, Artym VV, Green JA, Yamada KM: The matrix reorganized: extracellular matrix remodeling and integrin signaling. Curr Opin Cell Biol 2006, 18:463-471.
• [44]Ivaska J, Reunanen H, Westermarck J, Koivisto L, Kahari VM, Heino J: Integrin alpha2beta1 mediates isoform-specific activation of p38 and upregulation of collagen gene transcription by a mechanism involving the alpha2 cytoplasmic tail. J Cell Biol 1999, 147:401-416.
• [45]Galvez BG, Matias-Roman S, Yanez-Mo M, Sanchez-Madrid F, Arroyo AG: ECM regulates MT1-MMP localization with beta1 or alphavbeta3 integrins at distinct cell compartments modulating its internalization and activity on human endothelial cells. J Cell Biol 2002, 159:509-521.
• [46]Lehti K, Lohi J, Juntunen MM, Pei D, Keski-Oja J: Oligomerization through hemopexin and cytoplasmic domains regulates the activity and turnover of membrane-type 1 matrix metalloproteinase. J Biol Chem 2002, 277:8440-8448.
• [47]Itoh Y, Ito N, Nagase H, Evans RD, Bird SA, Seiki M: Cell surface collagenolysis requires homodimerization of the membrane-bound collagenase MT1-MMP. Mol Biol Cell 2006, 17:5390-5399.
• [48]Sameni M, Dosescu J, Yamada KM, Sloane BF, Cavallo-Medved D: Functional live-cell imaging demonstrates that beta1-integrin promotes type IV collagen degradation by breast and prostate cancer cells. Mol Imaging 2008, 7:199-213.
• [49]Wolf K, Wu YI, Liu Y, Geiger J, Tam E, Overall C, Stack MS, Friedl P: Multi-step pericellular proteolysis controls the transition from individual to collective cancer cell invasion. Nat Cell Biol 2007, 9:893-904.
• [50]Yu M, Sato H, Seiki M, Thompson EW: Complex regulation of membrane-type matrix metalloproteinase expression and matrix metalloproteinase-2 activation by concanavalin A in MDA-MB-231 human breast cancer cells. Cancer Res 1995, 55:3272-3277.
• [51]Finesmith TH, Broadley KN, Davidson JM: Fibroblasts from wounds of different stages of repair vary in their ability to contract a collagen gel in response to growth factors. J Cell Physiol 1990, 144:99-107.
• [52]Gullberg D, Tingstrom A, Thuresson AC, Olsson L, Terracio L, Borg TK, Rubin K: Beta 1 integrin-mediated collagen gel contraction is stimulated by PDGF. Exp Cell Res 1990, 186:264-272.
• [53]Carver W, Molano I, Reaves TA, Borg TK, Terracio L: Role of the alpha 1 beta 1 integrin complex in collagen gel contraction in vitro by fibroblasts. J Cell Physiol 1995, 165:425-437.
• [54]Takino T, Tsuge H, Ozawa T, Sato H: MT1-MMP promotes cell growth and ERK activation through c-Src and paxillin in three-dimensional collagen matrix. Biochem Biophys Res Commun 2010, 396:1042-1047.
• [55]Takino T, Guo L, Domoto T, Sato H: MT1-MMP prevents growth inhibition by three dimensional fibronectin matrix. Biochem Biophys Res Commun 2013, 436:503-508.
• [56]Stehbens SJ, Paszek M, Pemble H, Ettinger A, Gierke S, Wittmann T: CLASPs link focal-adhesion-associated microtubule capture to localized exocytosis and adhesion site turnover. Nat Cell Biol 2014, 16:561-573.
• [57]Wu X, Gan B, Yoo Y, Guan JL: FAK-mediated src phosphorylation of endophilin A2 inhibits endocytosis of MT1-MMP and promotes ECM degradation. Dev Cell 2005, 9:185-196.
• [58]Phillip S, Bulbule A, Kundu GC: Osteopontin stimulates tumor growth and activation of promatrix metalloproteinase-2 through nuclear factor-kappa B-mediated induction of membrane type I matrix metalloproteinase in murine melanoma cells. J Biol Chem 2001, 276:44926-44935.
• [59]Deryugina EI, Ratnikov B, Postnova TI, DiScipio R, Smith JW, Strongin AY: MT1-MMP initiates activation of pro-MMP-2 and integrin alphavbeta3 promotes maturation of MMP-2 in breast carcinoma cells. Exp Cell Res 2001, 263(2):209-223.
• [60]Chattopadhyay N, Aparna M, Frei E, Chatterjee A: Human cervical tumor cell (SiHa) surface αvβ3 integrin receptor has associated matrix metalloproteinase (MMP-2) activity. J Cancer Res Clin Oncol 2001, 127:653-658.